Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q1 FY25 Earnings Presentation
13 slides from Viyash Scientific's earnings presentation, Aug 15, 2024
Slide 1: Investor Presentation filing letter to stock exchanges
Proven Ability In Life Sciences August 15, 2024 To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip
Slide 2: Investor Presentation Q1 FY25
INVESTOR PRESENTATION Q1 FY25 SEQUENT SCIENTIFIC LIMITED 16th August 2024
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Q1 FY25 Performance Update
Q1 FY25 Performance Update ( eS,
Slide 5: Sequent Q1 FY25 – Earnings Release
Sequent Q1 FY25 – Earnings Release I am glad to share that the new financial year has started well for the company, and we continue to strengthen our performance, on the back of the transformation program which has been rolled out late last year. Our business has become more competitive as a result
Slide 6: Strong business performance – revenue and profit growth
Strong business performance – revenue and profit growth Revenues EBITDA (Pre ESOP) PAT All values in ₹ Mn ₹3,902 ₹483 ₹91 Million Million Million 17.1% 418.6% 126.0% YoY YoY YoY 8.0% 17.6% 607.1% QoQ QoQ QoQ The results include provision for a non recurring one off claim of Rs 86 mn. Excl this one o
Slide 7: Q1 FY25: Revenue Performance – breakup
Q1 FY25: Revenue Performance – breakup All values in ₹ Mn QnQ Gr% YoY Gr% Revenue Distribution Q1 FY25 Q4 FY24 QnQ Gr% Q1 FY24 YoY Gr% (In cc) (In cc) Formulations 3,002 2,476 21.3% 19.4% 2,478 21.1% 30.8% Europe 1,571 1,236 27.0% 27.5% 1,172 34.1% 33.6% Emerging Markets 1,187 1,007 17.9% 12.8% 1,05
Slide 8: Formulations: Accelerating partnerships and launches
Formulations : Accelerating partnerships and launches Highlights 1000+ • New Product Launches: Introduction of Dogstem in Sweden and Flortekxin in Spain, FDFs focusing on innovative healthcare solutions. • Increased Vaccine Sales: Strong growth in vaccine sales for Syvazul in Belgium and the Netherl
Slide 9: API: Margin and operational improvement. Quality growth
API : Margin and operational improvement. Quality growth Highlights 32 • Anthelmintic Demand : There has been a revival in demand for anthelmintic products Commercial APIs and preference for the Sequent quality grade. • Project Parivartan: A step change in Quality systems at the manufacturing locati
Slide 10: Approvals & Accreditations
Approvals & Accreditations U.S. FDA Approval Japanese Accreditation WHO Prequalification Secured a positive Establishment Obtained the Accreditation Achieved WHO PQ Approval for Inspection Report (EIR) for our Certificate of Foreign Animal Drug Albendazole API, underscoring our Animal Health API Fac
Slide 11: Q1 FY25 Financials
Q1 FY25 Financials
Slide 12: Q1 FY25 Consolidated Financials
Q1 FY25 Consolidated Financials All values in ₹ Mn Q1 Q4 Q1 Particulars Grw QnQ % Grw YoY % FY25 FY24 FY24 Revenue from Operations 3,902 3,612 3,332 8% 17% Key Notes Q1 Y-o-Y : Material Consumption (2,143) (1,945) (1,948) Gross Margin 1,759 1,667 1,384 6% 27% + 3.6% on YoY Gross % 45.1% 46.1% 41.5%
Slide 13: For details, feel free to contact
For details, feel free to contact: Phillip Trott Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 301/A, ‘Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, I